Article
An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype.
Toxicologic pathology - 1 Jan 2000
Weaver J L, Contrera J F, Rosenzweig B A, Thompson K L, Faustino P J, Strong J M, Ellison C D, Anderson L W, Prasanna H R, Long-Bradley P E, Lin K K, Zhang J, Sistare F D
Abstract excerpt
We have completed 2 26-wk studies to evaluate the hemizygous transgenic Tg.AC mouse, which has been proposed as an alternative short term model for testing carcinogenicity. We attempted to evaluate the response to the known rodent carcinogens cyclophosphamide, phenolphthalein, and tamoxifen and t...
Topics
- Administration, Topical
- Animals
- Carcinogenicity Tests
- Carcinogens
- Mice
- Mice, Transgenic
- Papilloma
- Phenotype
- Skin Neoplasms
- Weight Gain